• Johnson & Johnson will present more than 25 solid-tumor abstracts at the 2026 ESMO Congress, including first clinical results for JNJ-6143.
• The investigational oral prostate cancer drug’s safety and efficacy findings will guide dose selection following the December 2025 acquisition of Halda Therapeutics.
• Late-breaking Phase 3 PROTEUS results will assess perioperative Erleada treatment against surgery alone in high-risk localized or locally advanced prostate cancer.
• Initial OrigAMI-4 findings show encouraging tumor responses with Rybrevant Faspro combined with pembrolizumab and carboplatin in first-line recurrent or metastatic head-and-neck cancer.
• A separate indirect comparison found improved survival with Rybrevant Faspro monotherapy versus real-world therapies in previously treated head-and-neck cancer; results await presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.